Adoptive therapy using antigen-specific T-cell clones
- PMID: 20693849
- DOI: 10.1097/PPO.0b013e3181eacba8
Adoptive therapy using antigen-specific T-cell clones
Abstract
T-cell therapy involves the ex vivo isolation and expansion of antigen-specific T cells for adoptive transfer. The use of T-cell clones represents one embodiment of this approach and provides a uniform population of effector cells, so that parameters contributing to an effective response can be rigorously evaluated. T cells of defined specificity, phenotype, and function are isolated and expanded; when infused into patients, these intrinsic factors can be considered in light of extrinsic factors such as the type of conditioning regimen, cytokine support, and immunomodulatory reagents. In this chapter, 2 topics related to the use of antigen-specific T-cell clones are discussed: first, advances enabling the isolation and expansion of antigen-specific T-cell clones for human trials of adoptive therapy, and second, a contextual framework of advantages and limitations in which the use of adoptively transferred T-cell clones can be judiciously applied as a means to dissect the requirements for effective therapy.
Similar articles
-
Rebuilding human leukocyte antigen class II-restricted minor histocompatibility antigen specificity in recall antigen-specific T cells by adoptive T cell receptor transfer: implications for adoptive immunotherapy.Clin Cancer Res. 2007 Jul 1;13(13):4009-15. doi: 10.1158/1078-0432.CCR-07-0286. Clin Cancer Res. 2007. PMID: 17606735
-
Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming.Clin Cancer Res. 2007 Mar 15;13(6):1883-91. doi: 10.1158/1078-0432.CCR-06-2083. Clin Cancer Res. 2007. PMID: 17363545
-
Adoptive T-cell therapy of cancer.Hematol Oncol Clin North Am. 2006 Jun;20(3):711-33. doi: 10.1016/j.hoc.2006.02.008. Hematol Oncol Clin North Am. 2006. PMID: 16762731 Review.
-
HLA type-independent generation of antigen-specific T cells for adoptive immunotherapy.Eur J Immunol. 2005 Jul;35(7):2250-8. doi: 10.1002/eji.200526230. Eur J Immunol. 2005. PMID: 15915543
-
Adoptive T-cell therapy of cancer.J BUON. 2009 Sep;14 Suppl 1:S193-201. J BUON. 2009. PMID: 19785066 Review.
Cited by
-
Integrating multiplexed imaging and multiscale modeling identifies tumor phenotype conversion as a critical component of therapeutic T cell efficacy.Cell Syst. 2024 Apr 17;15(4):322-338.e5. doi: 10.1016/j.cels.2024.03.004. Cell Syst. 2024. PMID: 38636457 Free PMC article.
-
Dendritic cells in cancer immunotherapy: vaccines and combination immunotherapies.Expert Rev Vaccines. 2013 Mar;12(3):285-95. doi: 10.1586/erv.13.22. Expert Rev Vaccines. 2013. PMID: 23496668 Free PMC article. Review.
-
Abrogation of SRC homology region 2 domain-containing phosphatase 1 in tumor-specific T cells improves efficacy of adoptive immunotherapy by enhancing the effector function and accumulation of short-lived effector T cells in vivo.J Immunol. 2012 Aug 15;189(4):1812-25. doi: 10.4049/jimmunol.1200552. Epub 2012 Jul 13. J Immunol. 2012. PMID: 22798667 Free PMC article.
-
Adoptive immunotherapy for cancer: harnessing the T cell response.Nat Rev Immunol. 2012 Mar 22;12(4):269-81. doi: 10.1038/nri3191. Nat Rev Immunol. 2012. PMID: 22437939 Free PMC article. Review.
-
Cellular immunotherapy for carcinoma using genetically modified EGFR-specific T lymphocytes.Neoplasia. 2013 May;15(5):544-53. doi: 10.1593/neo.13168. Neoplasia. 2013. PMID: 23633926 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources